Thermo Fisher Scientific Inc

• Medline's stock rallied due to bargain-hunting and positive executive presentations at conferences. • The company reported annual revenue of $28.43B and a net profit of $1.16B. • Analysts issued Buy ratings with an average price target of $44.52.

• Natera's clinical milestones and Signatera validation bolstered investor confidence. • Management highlighted accelerating test adoption and long-term gross margin expansion. • Wall Street sentiment remains favorable with multiple analysts issuing buy ratings.

• Wall Street upgrades and UBS ratings changes drove Illumina stock upward. • Illumina will rejoin the S&P 500 index during rebalancing. • Annual revenue reached $4.34 billion with a net profit of $850 million.

• Natera reported strong adoption for Signatera and positive Medicare reimbursement updates. • The company achieved robust top-line revenue growth with $2.31B annual revenue. • Analysts issued Buy ratings with an average price target of $342.35.

• Danaher reaffirmed its third-quarter and full-year financial guidance. • Julie Sawyer Montgomery will assume the CEO role on October 1. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• UBS upgraded Illumina to Buy with a price target of $260. • Illumina will rejoin the S&P 500 index from the S&P MidCap 400. • The company reported strong NovaSeq X demand and consecutive earnings beats.